Piper Jaffray analyst Charles Duncan is out with a research note on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), previewing the drug maker’s upcoming earnings announcement, as well as …
Needham analyst Alan Carr is out with a mixed research report today on biotech players Gilead Sciences, Inc. (NASDAQ:GILD) and ACADIA Pharmaceuticals Inc.
As earnings season rolls to the foreground and key biotech players like Gilead Sciences, Inc. (NASDAQ:GILD), Merrimack Pharmaceuticals Inc (NASDAQ:MACK), ACADIA Pharmaceuticals Inc.
Cowen analyst Ritu Baral weighs in today on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), after the drug maker provided an update focusing on the ongoing launch of …
J.P.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) shares were shooting as if out of a canon on a 20% upturn this morning thanks to positive top-line …
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) announced positive top-line results from its Phase II exploratory study (-019 Study) of pimavanserin in patients with Alzheimer’s disease …
Cowen analyst Ritu Baral is out with a research report on shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) after conducting separate surveys of 25 …
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) announced the initiation of CLARITY, a Phase II study to evaluate pimavanserin for adjunctive treatment in patients with major …
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is anticipated to announce data from the Phase 2 trial of pimavanserin in Alzheimer’s Disease Psychosis (ADP) come December.
